Leukotriene enhances NMDA-induced inward currents in dorsal horn neurons of the rat spinal cord after peripheral nerve injury by unknown
Kiyoyuki et al. Mol Pain  (2015) 11:53 
DOI 10.1186/s12990-015-0059-5
RESEARCH
Leukotriene enhances NMDA-induced 
inward currents in dorsal horn neurons of the 
rat spinal cord after peripheral nerve injury
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Abstract 
Background: LTB4 is classified as a leukotriene (LT), a group of lipid mediators that are derived from arachidonic acid. 
It is recognized that leukotrienes are involved in the pathogenesis of many diseases, including peripheral inflamma-
tory pain. However, little is known about the effects of leukotrienes on the spinal dorsal horn during neuropathic 
pain. Previously, we reported that there was increased expression of 5-lipoxygenase (5-LO) at spinal microglia, and the 
leukotriene B4 receptor 1 (BLT1), a high affinity receptor of LTB4, in spinal neurons in spared nerve injury (SNI) model 
rats. In the present study, we examined the effects of LTB4 on spinal dorsal horn neurons in both naïve and SNI model 
rats using patch-clamp methods.
Results: Bath application of LTB4 did not change AMPA receptor-mediated spontaneous excitatory postsynaptic 
currents (sEPSCs) or membrane potentials. However, we found that LTB4 enhanced the amplitude of NMDA receptor-
mediated sEPSCs and significantly increased exogenous NMDA-induced inward currents in SNI model rats. This 
increase of inward currents could be inhibited by a selective LTB4 antagonist, U75302, as well as a GDP-β-S, a G-pro-
tein inhibitor. These results indicate that both increased LTB4 from spinal microglia or increased BLT1 in spinal neurons 
after peripheral nerve injury can enhance the activity of NMDA receptors through intracellular G-proteins in spinal 
dorsal horn neurons.
Conclusion: Our findings showed that LTB4, which may originate from microglia, can activate BLT1 receptors which 
are expressed on the membrane of spinal dorsal horn neurons during neuropathic pain. This glia-neuron interaction 
induces the enhancement of NMDA currents through intracellular G-proteins. The enhancement of NMDA receptor 
sensitivity of dorsal horn neurons may lead to central sensitization, leading to mechanical pain hypersensitivity.
© 2015 Kiyoyuki et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Nociceptive pathways are recognized to be dynami-
cally modulated by gene expression, protein synthesis, 
and intracellular signaling after peripheral nerve injury 
[1–3]. Particularly, activated glial cells in the spinal cord 
after peripheral nerve injury produce and release pro-
inflammatory cytokines, such as interleukin-1 beta 
(IL-1β), tumor necrosis factor-alpha (TNF-α), and neu-
rotrophins, resulting in the enhancement of excitability 
in nociceptive dorsal horn neurons [4–8]. Recently, 
lipid mediators, their receptors, and proinflammatory 
cytokines have become considered some of most inter-
esting molecules in pain research [9–11]. Accumulating 
evidence suggests that lipid mediators, such as prosta-
glandins (PG), lysophosphatidic acid, platelet-activating 
factor, and their receptors, have critical roles in nocicep-
tive pathways and pathological pain [12–14].
Leukotrienes (LTs) are a group of lipid mediators 
derived from arachidonic acid (AA). LTs include sev-
eral products catalyzed in the 5-lipoxygenase (5-LO) 
pathway that are then released from the cell membrane. 
LTs have a variety of biological actions and have been 
recognized as important factors in numerous disease 
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processes, including allergic diseases (e.g. asthma, atopic 
dermatitis), local or systemic inflammatory diseases (e.g. 
rheumatoid arthritis, psoriasis), cancer, and cardiovascu-
lar diseases [15, 16]. AA is converted to leukotriene A4 
(LTA4) which is then converted to LTB4, LTC4, LTD4, 
or LTE4. These products are known as bioactive leukot-
rienes. LTC4, LTD4 and LTE4 are collectively termed 
‘cysteinyl leukotrienes’ (CysLTs). LTs act by binding to 
specific receptors which are located on the outer plasma 
membrane of structural and inflammatory cells [15]. So 
far, four G-protein coupled receptors have been cloned 
and characterized as LTs receptors [17–20]. It is recog-
nized that the LTB4 receptor 1 (BLT1) has a high affinity 
for LTB4, but that BLT2 has a low affinity for LTB4 and 
many other LTs. Studies have shown that lipid media-
tors have a key role in the pain mechanisms of peripheral 
inflammation, while other research indicates the involve-
ment of spinal lipoxygenase metabolites in hyperalgesic 
responses [16]. For example, prostaglandin E2(PGE2) 
directly depolarizes spinal dorsal horn neurons via the 
prostaglandin E receptor 2 (EP2)-like receptor, resulting 
in the enhancement of dorsal horn neuronal excitability 
[9]. Lysophosphatidic acid may be released in the spinal 
cord after nerve injury and affect the excitability of dor-
sal horn neurons, which may be involved in hyperalgesia 
after peripheral nerve injury [12, 21]. Some studies indi-
cate that LTs and their synthesizing enzymes are present 
in the central nervous system, including the spinal cord, 
and play important roles in both normal and pathological 
states [22–24].
Previously, we reported that BLT1 mRNA was 
expressed by non-neuronal cells in DRG and that CysLT2 
mRNA was preferentially expressed by small DRG neu-
rons [25, 26]. Furthermore, we showed that the expres-
sion of 5-LO in spinal microglia and BLT1 mRNAs in 
spinal neurons (especially laminae III–IV) was increased 
during peripheral nerve injury using immunohistochem-
istry, reverse transcription-polymerase chain reaction 
(RT-PCR), in  situ hybridization histochemistry (ISHH), 
and behavioral experiments [25]. These findings suggest 
that LTB4 contributes to the central sensitization of the 
spinal cord after peripheral nerve injury. However, it is 
unclear how LTB4 acts on excitatory neurotransmission 
in the spinal dorsal horn. In the present study, we exam-
ine how LTB4 modulates excitatory neurotransmission in 
the spinal dorsal horn after nerve injury.
Results
Whole-cell patch-clamp recordings were made from a 
total of 181 spinal dorsal horn neurons. Stable record-
ings were obtained from slices more than 12 h after the 
dissection, and recordings were made from single dorsal 
horn neurons for up to 4 h.
BLT1, the receptor of LTB4, increased in laminae III‑IV in SNI 
model rats
In order to show that BLT1 mRNA expression is 
increased in the laminae after peripheral nerve injury, 
we performed RT-PCR and in  situ hybridization histo-
chemistry of dorsal horn tissue. We confirmed that SNI 
induced the expression of BLT1 mRNA significantly 
compared to naïve rats (Fig. 1a). We found a majority of 
neurons showing apparent increase of BLT1 mRNA were 
located in laminae III-IV (Fig. 1b, c). Thus, our next step 
was to examine the effect of LTB4 on laminae III–IV neu-
rons using patch-clamp recording.
LTB4 had no effect on AMPA receptor‑mediated 
neurotransmission in rat spinal dorsal horn neurons
All the recorded neurons that were tested exhibited 
spontaneous excitatory postsynaptic currents (sEP-
SCs) at a holding potential (VH) of −70  mV, at which 
no inhibitory postsynaptic currents (IPSCs) were 
observed because the reversal potential for IPSCs was 
near −70  mV [27]. To examine the effects of LTB4 on 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
Fig. 1 BLT1 mRNA increased in dorsal horn neurons after peripheral 
nerve injury. a Expression of BLT1 mRNA in the ipsilateral spinal cord 
following SNI surgery by conventional RT-PCR. Upper gel panels show 
PCR products from the dorsal horn of the L4–5 spinal cord taken from 
naïve and 7 days after SNI. Lower histogram shows the quantification 
of relative BLT1 mRNA levels (mean ± SEM; *, P < 0.05 compared with 
naïve). b, c Bright-field images of in situ hybridization showing BLT1 
mRNA expression in lamina III of the spinal dorsal horn in naïve (b) 
and 7 days after SNI (c). Solid arrowheads indicate the positive cells. 
Scale bar 25 µm
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(AMPA) receptor-mediated excitatory synaptic trans-
mission, LTB4 (10 μM) was dissolved in Krebs solution 
and was applied by perfusion for 1  min. When the cell 
membrane is fixed at −70  mV, N-methyl-d-aspartate 
(NMDA) receptors are blocked by Mg2+. The frequency 
and amplitude of sEPSC were not affected by applica-
tion of LTB4 in dorsal horn neurons (n  =  14) of naïve 
rats (Fig.  2a). The frequency and the amplitude were, 
respectively, 116.1 ± 7.4 % (n = 14, P > 0.05) of control 
(1.2 ±  0.4  Hz) and 105.2 ±  3.9  % (n =  14, P  >  0.05) of 
control (8.5 ± 1.8 pA, Fig. 2b). The frequency and ampli-
tude of sEPSC also were not affected by the application 
of LTB4 in dorsal horn neurons (n = 19) of spared nerve 
injury (SNI) model rats (Fig.  2c, d). The frequency and 
the amplitude were, respectively, 112.6 ± 9.7 % (n = 19, 
P  >  0.05) of control (1.8  ±  0.4  Hz) and 103.5  ±  3.6  % 
(n = 19, P > 0.05) of control (7.1 ± 0.2 pA, Fig. 2d). These 
results indicate that LTB4 does not affect AMPA recep-
tor-mediated sEPSC of dorsal horn neurons in either 
naïve or SNI rats.
Next, we investigated whether LTB4 affects AMPA-
induced currents in dorsal horn neurons. Exogenous 
application of AMPA (10 μM) for 30  s induced inward 
currents at a holding potential of −70  mV. After 30  s 
pretreatment of LTB4 (10  μM) in naïve rats, AMPA-
induced inward currents did not change (n = 11, Fig. 3a). 
The average peak amplitude of AMPA-induced currents 
was 100.1 ± 4.9 % of the control (24.5 ± 3.6 pA, Fig. 3b). 
Next, we examined LTB4 effects in SNI model rats. 
AMPA-induced currents of SNI model rat also did not 
change (n = 13, Fig. 3c). The average peak amplitude of 
AMPA-induced currents was 102.9 ± 7.4 % of the control 
(24.5 ± 3.6 pA, Fig. 3d). The application of LTB4 did not 
affect AMPA-induced currents of dorsal horn neurons in 
either naïve or SNI rats.
LTB4 enhanced postsynaptic NMDA currents in spinal 
dorsal horn neurons of SNI model rats
Application of LTB4 alone had no effect on AMPA recep-
tor-mediated excitatory neurotransmission of dorsal 
horn neurons. However, our previous behavioral tests 
suggested that LTB4 contributes to neuropathic pain 
[25]. Next, we investigated whether LTB4 was involved 
in NMDA receptors response, because NMDA recep-
tors are well known to contribute to neuropathic pain. 
First, we examined whether LTB4 affects NMDA recep-
tor-mediated sEPSCs. We recorded NMDA receptor-
mediated sEPSCs at a holding potential of +40  mV to 
completely release Mg2+ blockage of NMDA receptors. 
Under this condition, we performed the experiment 
during the simultaneous application of 6-cyano-7-nit-
roquinoxaline-2,3-dione (CNQX) (10  μM), an AMPA 
receptor antagonist, bicuculline (20  μM), a GABA 
receptor antagonist, and strychnine (2  μM), a glycine 
receptor antagonist, to distinguish it from IPSCs and 
AMPA receptor-mediated sEPSCs. In naïve rats the aver-
age increases in NMDA receptor-mediated sEPSC fre-
quency and amplitude mediated by LTB4 (10 μM) were 
104.1  ±  7.2  % and 99.8  ±  13.4  % (n  =  5), respectively 
(Fig.  4b). These values were not significantly different 
from control (P  <  0.05). However, we found that LTB4 
slightly enhanced the amplitude of NMDA receptor-
mediated sEPSCs in SNI model rats (Fig. 4a). The average 
increases in NMDA receptor-mediated sEPSC frequency 
and amplitude mediated by LTB4 were 107.8 ± 7.0 % and 
109.6 ± 2.6 % (n = 5), respectively (Fig. 4c). This increase 
in amplitude was significantly large compared to control 
(P < 0.05). These results suggest LTB4 enhanced postsyn-
aptic NMDA receptor actions in the neuropathic pain 
model. Therefore, we examined whether LTB4 affects 
postsynaptic NMDA currents in dorsal horn neurons.
Exogenous application of NMDA (30  μM) for 30  s 
induced inward currents at a holding potential of 
−50  mV. After 30  s pretreatment of LTB4 (10  μM) in 
naïve rats, NMDA-induced inward currents did not 
change (n = 28, Fig. 5a). The average peak amplitude of 
NMDA-induced currents was 103.6 ± 3.9 % of the con-
trol (8.8 ± 1 pA, Fig. 5b). In the dorsal horn neurons of 
SNI model rats, we found that NMDA-induced currents 
increased in the presence of LTB4 in 28 neurons among 
91 neurons with NMDA-induced currents (38.1  %, 
Fig. 5c). The average-peak amplitude of NMDA-induced 
currents was 179.3  ±  5.8  % of control (8.8  ±  0.8  pA, 
Fig.  5d). These findings suggest that LTB4 enhanced 
NMDA currents in spinal dorsal horn neurons in SNI 
model rats, but not in the naïve rats.
A selective BLT1 antagonist inhibits NMDA currents 
induced by LTB4
BLT1 is a high affinity receptor for LTB4. To assess if 
the effects of LTB4 on NMDA-induced currents in dor-
sal horn neurons are mediated by BLT1, we investigated 
the effects of the presence of a selective BLT1 antagonist 
(U75302). In these experiments, U75302 (20  μM) was 
applied 2 min before treatment with LTB4 (10 μM), and 
the drug remained present while the agonist was being 
applied and during subsequent stimulation with NMDA 
(30  μM). The LTB4-induced enhancement of NMDA 
currents was significantly inhibited by U75302 (n  =  5, 
Fig. 6a). The average peak amplitude of NMDA-induced 
currents in the absence and the presence of U75302 
respectively were 177 ± 14.4 % and 117.6 ± 3.5 % of con-
trol (10.7 ± 2.8 pA, Fig. 6b). In order to exclude the possi-
ble non-specific effect of U75302, we found that U75302 
itself had no significant effect on NMDA-induced cur-
rents (n  =  9, Fig.  6c). The average-peak amplitude of 
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Fig. 2 LTB4 had no effects on AMPA receptor-mediated sEPSC in spinal dorsal horn neurons. The frequency and amplitude of sEPSC were not 
affected by application of LTB4 in dorsal horn neurons of either naïve (a, b) or SNI model rats (c, d). Bar graphs showing the average frequency and 
amplitude of sEPSC under the treatment with LTB4 (black bar), relative to those before this treatment (control, open bar) in naïve (b) and SNI model 
rats (d) (naïve; n = 14. SNI; n = 19, mean ± SEM). n.s., not significant
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NMDA-induced currents was 92.5  ±  4.5  % of control 
(14.9 ± 1.2 pA, Fig. 6d). These findings suggest that LTB4 
exerts its actions through BLT1, and enhances NMDA-
induced currents.
Involvement of G‑proteins in the LTB4 enhancement 
of NMDA currents
To examine the involvement of G-proteins in the 
increased NMDA-induced current by LTB4, GDP-β-S 
(2 mM), a non-hydrolysable analogue of GDP that com-
petitively inhibits G-proteins, was added to the pipette 
solution. When LTB4 (10  μM) and NMDA (30  μM) 
were applied just after establishing the whole-cell con-
figuration with pipettes containing potassium glu-
conate and GDP-β-S, NMDA-induced currents were 
clearly observed. However, when LTB4 and NMDA were 
again applied 30  min later, it significantly suppressed 
NMDA-induced currents (n  =  5, Fig.  7a). The average 
peak amplitudes of NMDA-induced currents respec-
tively were 170.2 ± 13.1 % and 113.5 ± 4.8 % of control 
(8.2  ±  1.1  pA, Fig.  7b). These findings suggest that the 
increased NMDA-induced currents by LTB4 were medi-
ated through the activation of G-proteins.
Discussion
In the present study, we examined the effects of LTB4 in 
the spinal dorsal horn neurons in laminar III–IV using 
whole-cell patch-clamp recording. The main findings 
are: (1) The frequency and amplitude of AMPA recep-
tor-mediated sEPSC and AMPA-induced currents in 
dorsal horn neurons were not affected by application of 
LTB4 in either naïve or SNI model rats. (2) In contrast, 
Fig. 3 LTB4 did not affect AMPA currents in spinal dorsal horn neurons of both naïve and SNI model rats. AMPA-induced currents were not affected 
by application of LTB4 in either naïve (a) or SNI model rats (c) dorsal horn neurons. b, d Bar graphs showing the average AMPA-induced currents 
under the treatment with LTB4 (black bar), relative to those before this treatment (control, open bar) in naïve (b) and SNI model rats (d) (naïve; 
n = 11. SNI; n = 13). n.s., not significant
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Fig. 4 The effects of LTB4 on NMDA receptor-mediated sEPSCs. a NMDA receptor-mediated sEPSC has a reversed waveform with slow decay at a 
holding potential of +40 mV. Three consecutive traces of EPSCs are shown in an expanded scale in time, before (bottom left) and under the action 
of LTB4 (bottom right). LTB4 slightly enhanced the amplitude of NMDA receptor-mediated sEPSCs in spinal dorsal horn neurons of SNI model rats. b, 
c Bar graphs showing the average frequency and amplitude of NMDA receptor-mediated sEPSC under the treatment with LTB4 (black bar), relative 
to those before this treatment (control, open bar) in naïve (b) and SNI model rats (c) (naïve; n = 5. SNI; n = 5). Statistical significance between data 
shown by bars is indicated by an asterisk; *, P < 0.05; n.s., not significant
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the perfusion of LTB4 enhanced both the amplitude 
of NMDA receptor-mediated sEPSC and exogenous 
NMDA-induced inward currents in spinal dorsal horn 
neurons of SNI model rats. However, this enhancement 
of LTB4 on NMDA responses was not observed in naïve 
rats. (3) The increase of NMDA-induced inward currents 
was inhibited by a LTB4 antagonist, U75302, as well as a 
GDP-β-S, a G-protein inhibitor.
We performed blind whole-cell patch-clamp record-
ings from laminae III-IV dorsal horn neurons. Expression 
of the LTs receptor had not been examined in the spinal 
cord until we recently showed that the subfamily of LTs 
receptors, BLT1 and CysLT1, are expressed in the gray 
matter in the spinal cord [25]. BLT1 was localized only 
in neurons, while CysLT1 was localized in only microglia. 
One of the important findings was that the expression of 
BLT1 increased in the spinal cord of SNI model rats at 
7 days after the peripheral nerve injury. The signal inten-
sity of BLT1 mRNA in the dorsal horn was very low in 
naïve rats and it was significantly elevated in SNI model 
rats (Fig.  1). Because a majority of neurons expressing 
increased BLT1 mRNA were located in laminae III–IV, 
we endeavored to record the neuronal activity in laminae 
III–IV after peripheral nerve injury.
LTs are lipid mediators with a proinflammatory profile 
that have been implicated in the pathogenesis of several 
types of inflammation [28]. For example, the blood and 
synovial fluids of patients with rheumatoid arthritis con-
tain higher levels of LTB4 than found in healthy subjects 
[29]. LTB4 is known as a potent neutrophil chemotactic 
Fig. 5 Enhanced NMDA currents by LTB4 in spinal dorsal horn neurons of SNI model rats. a LTB4 did not change NMDA-induced inward currents in 
naïve rats (n = 28). b Bar graph showing the average increase rate of NMDA-induced inward currents in naïve rats (open bar; control (NMDA alone), 
black bar; LTB4 + NMDA) (n = 28). c NMDA-induced inward currents in the presence of LTB4 were enhanced compared to without LTB4. d Bar graph 
showing the average increase rate of NMDA-induced inward currents in SNI model rats (open bar; control (NMDA alone), black bar; LTB4 + NMDA) 
(n = 28). *, P < 0.05; n.s., not significant
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agent. It is believed that in rheumatoid arthritis, neutro-
phils infiltrate synovial fluids and produce LTB4 inducing 
the inflammatory condition. Several studies have demon-
strated that LTs are involved in peripheral inflammatory 
pain [30–32]. Bisgaard et  al. demonstrated a reduction 
of the pain threshold in humans after intracutaneous 
deposition of LTB4 [30]. Also, both a LTB4 antagonist 
and BLT1 knockout mice showed reduced pain behav-
iors in inflammatory pain models [33]. It is well known 
that nerve growth factor (NGF) is up-regulated in 
Fig. 6 A selective BLT1 antagonist inhibited LTB4-induced enhancement of NMDA currents. a Enhancement of NMDA-currents by LTB4 was signifi-
cantly inhibited in the presence of the selective BLT1 antagonist, U75302 (20 μM). b Bar graph showing the average increase rate of NMDA-induced 
inward currents by NMDA alone as control (open bar) and under the treatment with LTB4 (black bar) and in the presence LTB4 during application 
U75302 (gray bar), (n = 5). c U75302 had no effect on NMDA-induced currents (n = 9). d Bar graph showing the average increase rate of NMDA-
induced inward currents by NMDA alone as control (open bar) and under the treatment with U75302 (black bar).  *, P < 0.05
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inflammatory tissue and sensitizes nociceptors [34], lead-
ing to thermal hyperalgesia [35]. It has also been reported 
that NGF increased LTB4 in the rat paw skin. These 
results suggest the participation of LTB4 in NGF-induced 
local thermal hyperalgesia [36]. Other study groups have 
reported that intrathecal administration of LTB4 leads 
to thermal hyperalgesia [37]. These previous reports 
indicate that LTs have important roles in chronic pain at 
peripheral tissues, especially inflammatory pain. How-
ever, few reports have suggested that LTs are involved in 
the neuropathic pain via central sensitization in the spi-
nal cord.
Our previous study showed that 5-LO and FLAP 
mRNAs increased in spinal microglia after SNI surgery 
[25]. 5-LO is the most important enzyme in the synthe-
sis of LTs. FLAP enhances the ability of 5-LO to inter-
act with its substrate. This finding suggests that LTs are 
synthesized in the activated spinal microglia after SNI. 
Together with the increase of BLT1 in spinal dorsal 
horn neurons after SNI, these findings suggest a pos-
sible interaction of activated microglia and neurons in 
the spinal cord. The purpose of this study was to dem-
onstrate whether LTB4 affects the neuronal activity in 
dorsal horn neurons by using whole cell patch-clamp 
recordings. We found that bath application of LTB4 did 
not increase AMPA receptor-mediated sEPSCs or mem-
brane potential. In contrast, LTB4 significantly enhanced 
both the amplitude of NMDA receptor-mediated sEP-
SCs and exogenous NMDA-induced inward currents in 
SNI model rats. LTB4 application did not affect sEPSC 
and NMDA-induced currents in naïve rats. It is probably 
because the expression of the BLT1 in naïve rats was very 
low as shown in Fig. 1.
Ionotropic glutamate receptors in the spinal dor-
sal horn have emerged as targets of analgesics during 
the last decade. It is widely known that activation of 
NMDA receptors is very important and essential step 
in both initiating and maintaining activity-dependent 
Fig. 7 Involvement of G-proteins in the LTB4-induced enhancement of NMDA currents. NMDA-induced currents were recorded with a potassium 
gluconate pipette solution containing GDP-β-S (2 mM). a NMDA-induced currents were recorded with potassium gluconate pipette solution con-
taining GDP-β-S. b Bar graphs showing the average increase rate of NMDA-induced inward currents by alone NMDA as control (open bar) and under 
the treatment with LTB4 (black bar) and in the presence LTB4 after 30 min (gray bar), (n = 5). *, P < 0.05
Page 10 of 13Kiyoyuki et al. Mol Pain  (2015) 11:53 
central sensitization and critically contributes to the 
development of pain hypersensitivity after peripheral 
tissue damage or nerve injury [38, 39]. In this study, the 
enhancements of NMDA-induced currents and sEPSC 
by LTB4 were demonstrated using the patch-clamp 
technique, which was consistent with the previous mor-
phological data [25]. Moreover, the increase of NMDA 
current was significantly reduced by the BLT1 selec-
tive antagonist. Together, this data suggests that LTB4 
increases after peripheral nerve injury, binds BLT1 in 
dorsal horn neurons and leads to the enhancement of 
excitatory neurotransmission via modulation of NMDA 
receptor.
The findings in this study suggest that LTB4 did not 
affect AMPA receptor at either the pre- or the post-syn-
aptic sites in the dorsal horn. The reason why LTB4 has 
excitatory effects on NMDA-mediated neuronal activ-
ity and not on AMPA-mediated activity is unknown. To 
clarify this point, the precise downstream signaling after 
BLT1 activation is necessary [40, 41]. Increased NMDA-
induced currents by LTB4 were completely blocked by 
the G-protein inhibitor GDP-β-S in the pipette solution, 
suggesting that BLT1 activation by LTB4 could enhance 
the sensitivity of NMDA receptors through intracellular 
G-proteins. This is a fundamental finding and requires 
more research on the precise mechanisms of signaling 
pathways to NMDA receptor subunits.
We previously reported that the continuous intrathecal 
injection of 5-LO inhibitors and LTs receptor antagonists 
significantly suppressed the development of mechani-
cal hypersensitivity after SNI, but late application from 
6 days after injury for 1 week did not reverse the mechan-
ical hypersensitivity [25]. This finding indicates that LTB4 
has a mechanistic role in neuropathic pain development. 
In this study, we performed the patch-clamp experiment 
on the spinal cord of rats 7–10 days after SNI. This timing 
was set to match the peak time point of increase of the 
expression of the BLT1 receptor in dorsal horn neurons. 
We should note the ineffectiveness in behavioral experi-
ments in vivo, despite the fact that the BLT1 antagonist 
significantly suppressed the NMDA-induced current 
in dorsal horn neurons during this time period. It must 
be considered that the concentration of the antagonist 
in  vivo is uncertain when it is intrathecally delivered. It 
is not easy to compare the conditions between intrathe-
cal application into living animals and bath application 
onto a slice preparation. Another point which should be 
considered is that multiple molecules or pathways may 
be activated and contribute to the pain hypersensitivity 
in this period. For example, spinal astrocytes may be an 
important player that release proinflammatory cytokines 
and chemokines to enhance and prolong neuropathic 
pain [42, 43]. These molecules from astrocytes might 
increase the excitability of dorsal horn neurons in addi-
tion to lipid mediators including LTB4. Total net effects 
on dorsal horn neurons should reflect the changes in pain 
behaviors.
Under physiological conditions, sensory modalities are 
associated with dorsal horn lamination. Consistent with 
this pattern of afferent termination, dorsal horn second 
order neurons in the superficial laminae mainly receive 
nociceptive input while neurons in deeper dorsal horn 
laminae mostly convey non-nociceptive (lamina III) or 
converged input (laminae IV–VI) [44, 45]. However, in 
pathological conditions such as peripheral nerve injury, 
previous studies have indicated that laminae III–IV neu-
rons with dorsal column nuclei showed dynamic changes 
and may have a role in the abnormal processing of input 
in the spinal cord which leads to mechanical hypersen-
sitivity [46–48]. The enhancement of NMDA-medi-
ated responses via BLT1 in SNI rats may be involved 
in the sensitization in laminae III–IV and result in the 
increase of neuronal activity, leading to neuropathic pain 
behaviors.
Currently, little is known about the mechanisms that 
induce LT synthetases in spinal microglia, or what leads 
the BLTl to be expressed in dorsal horn neurons. LTB4 
in the spinal cord must be an important mediator in neu-
ropathic pain, like other lipid mediators, prostaglandins 
and lysophosphatidic acid [3, 21]. It is also possible that 
other types of cells in the spinal cord produce LTB4 or 
other LTs after peripheral nerve injury, because previous 
papers using cell cultures reported the synthesis of LTB4 
in astrocytes, oligodendrocytes and endothelical cells 
[49–51]. We believe that lipid mediators such as LTB4 
might be important players in neuron-glia interaction 
and have a role in pain hypersensitivity via activation of 
NMDA-mediated responses in the dorsal horn neuron 
after peripheral nerve injury. The investigation of LTB4 
and BLT1 may not only lead to a deeper understanding of 
intractable neuropathic pain, but also have the potential 
to find therapeutic agents in the future.
Conclusion
Our findings showed that LTB4, which may originate 
from microglia, could activate BLT1 receptors, which are 
expressed on the membrane of spinal dorsal horn neu-
rons during neuropathic pain. LTB4 enhanced both the 
amplitude of NMDA receptor-mediated sEPSC and exog-
enous NMDA-induced inward currents in dorsal horn 
neurons of SNI model rats. The enhancement of NMDA 
currents is through intracellular G-proteins; however 
the detailed mechanisms of the downstream signaling 
and the glia-neuron interaction in the spinal cord need 
further study in order to be clarified. We believe that 
the LTB4-BLT1 mechanism in the spinal cord may be 
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involved in central sensitization after peripheral nerve 
injury.
Methods
All of the experimental procedures involving the use of 
animals were approved by the Ethics Committee on Ani-
mal Experiments, Kansai University of Health Sciences 
and the Hyogo College of Medicine Committee on Ani-
mal Research, and were in accordance with the United 
Kingdom Animals (Scientific Procedures) Act of 1986 
and associated guidelines. Every effort was made to mini-
mize animal suffering and reduce the number of animals 
used.
Animal procedures
Male adult Sprague–Dawley rats (4–5 weeks of age, 130–
200  g) were divided into neuropathic pain model and 
naïve rat groups. Neuropathic pain model rats were anes-
thetized with sodium pentobarbital (50 mg kg−1, ip) and 
received SNI in their hindlimbs [52]. Briefly, the sciatic 
nerve was exposed at the level of its trifurcation into the 
sural, tibial, and common peroneal nerves. Each of the 
tibial and common peroneal nerves were tightly ligated 
by silk and then completely severed in between, leaving 
the sural nerve intact. SNI model rats were used in exper-
iments 7–10 days after surgery.
Reverse transcription‑polymerase chain reaction (RT‑PCR) 
and in situ hybridization histochemistry
Methods of RT-PCR and in situ hybridization histochem-
istry were described in detail in our previous paper [25].
Spinal cord slice preparations
The methods used for obtaining adult rat spinal cord 
slice preparations have been described previously [53]. 
In brief, adult rats were deeply anesthetized with ure-
thane (1.2 g/kg, IP), and then lumbosacral laminectomy 
was performed. The lumbosacral spinal cord (L1–S3) was 
removed and placed in pre-oxygenated sucrose-artificial 
cerebrospinal fluid (ACSF) at 1–3 °C. Sucrose-ACSF con-
tained the following (in mM): 223 sucrose, 25 NaHCO3, 
1.2 NaH2PO4, 3.6 KCL, 2 CaCl2, 1 MgCl2, 0.4 ascorbic 
acid, 2 pyruvate, 11 glucose and pH 7.4 [54]. Immedi-
ately after the removal of the spinal cord, the rats were 
given an overdose of urethane and were then killed 
by exsanguination. The pia-arachnoid membrane was 
removed after cutting all of the ventral and dorsal roots 
near the root entry zone. The spinal cord was mounted 
on a microslicer and then a 600-μm-thick transverse 
slice was cut from the lumbar segment which mainly L4 
or L5 root entries. The slice was placed on a nylon mesh 
in the recording chamber, which had a volume of 0.5 ml, 
and then perfused at a rate of 10–15 ml/min with Krebs 
solution saturated with 95 % O2 and 5 % CO2, and main-
tained at 36 ± 1 °C. The Krebs solution contained the fol-
lowing (in mM): 117 NaCl, 3.6 KCl, 2.5 CaCl2, 1.2 MgCl2, 
1.2 NaH2PO4, 25 NaHCO3 and 11 glucose, pH 7.4.
Patch‑clamp recordings from spinal dorsal horn neurons
Blind whole-cell patch-clamp recordings were made from 
spinal dorsal horn neurons (lamina III–IV) with patch-
pipette electrodes having a resistance of 5–10  MΩ. The 
patch-pipette solution used to record EPSCs was com-
posed of the following (in mM): 135 potassium gluco-
nate, 5 KCl, 0.5 CaCl2, 2 MgCl2, 5 EGTA, 5 HEPES and 
5 ATP-Mg, pH 7.2. Recording of NMDA receptor-medi-
ated sEPSCs was performed using an electrode solution 
composed of the following (mM): Cs2SO4 110, tetraeth-
ylammonium 5, CaCl2 0.5, MgCl2 2, EGTA 5, ATP-Mg 
5 and HEPES–KOH 5; pH 7.2 (305  mOsm). Membrane 
potentials were held at −70 mV in voltage-clamp mode. 
After making a gigaohm seal, the membrane patch was 
ruptured by a brief period of more negative pressure, 
thus resulting in a whole cell configuration. Signals were 
acquired with a patch-clamp amplifier (Axopatch 200B; 
Molecular Devices, Sunnyvale, CA, USA). Data were 
digitized with an analog-to-digital converter (Digidata 
1440A; Molecular Devices) and stored on a personal 
computer using the pCLAMP 10 data acquisition pro-
gram (Molecular Devices). In this study, the exogenous 
NMDA currents were recorded at −50 mV, and the exog-
enous AMPA currents were recorded at −70  mV. The 
frequency and amplitude of the sEPSCs when exposed 
to LBT4 were analyzed at −70 mV (AMPA receptor) and 
+40  mV (NMDA receptor). Data were analyzed using 
Mini Analysis 6.0 software (Synaptosoft, Fort Lee, NJ, 
USA) and the pCLAMP 10 data acquisition program. 
EPSCs were detected with Mini Analysis by setting the 
following parameters: amplitude threshold, 5 pA and area 
threshold, 20 pA × ms with their fast rise time and decay 
curve. Spinal dorsal horn neurons were viable for up to 
24 h in slices perfused with pre-oxygenated Krebs solu-
tion, although all of the recordings described here were 
obtained within 12 h. Whole-cell patch-clamp recordings 
were stable for up to 4 h. The membrane potentials were 
not corrected for the liquid junction potential between 
the Krebs and patch-pipette solutions.
Application of the drugs
Drugs were dissolved in Krebs solution and applied 
by perfusion via a three-way stopcock without any 
change in the perfusion rate or the temperature. The 
time necessary for the solution to flow from the stop-
cock to the surface of the spinal cord was ~30  s. The 
drugs used in this study were LTB4 (5S,12R-dihydroxy-
6Z,8E,10E,14Z-eicosatetraenoic acid), BLT1 receptor 
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antagonist U75302 (6-(6-(3R-hydroxy-1E,5Z-undeca-
dien-1-yl)-2-pyridinyl)-1,5S-hexanediol) (Sigma, Poole, 
UK), GDP-β-S (Sigma, St Louis, MO, USA), AMPA, 
NMDA, CNQX, bicuculline, and strychnine (Sigma-
Aldrich, St. Louis, MO, USA). AMPA and NMDA were 
first dissolved in distilled water at 1000 times the concen-
tration to be used, while CNQX, bicuculline, and strych-
nine were first dissolved in dimethyl sulfoxide at 1000× 
the concentration to be used. They were then stored at 
−20 °C and were diluted to the desired concentration in 
Krebs solution immediately before use. LTB4 and U75302 
were stored in ethanol at −20 °C. The ethanol was evapo-
rated from the drugs under a gentle stream of nitrogen 
immediately before use.
Statistical analysis
All numerical data were expressed as the mean ± S.E.M. 
Paired Student’s t tests were used to determine the statis-
tical significance between means. P < 0.05 was considered 
significant for these tests. For the electrophysiological 
data, “n” refers to the number of neurons studied.
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